Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists

In cancer, immune checkpoint inhibitors (ICIs) improve patient survival but may lead to severe immune-related adverse events (irAEs). Rheumatic irAEs are a distinct entity that are much more common in a real-life than in clinical trial reports due to their unspecific symptoms and them being a rare c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacholczak-Madej, Renata, Kosałka-Węgiel, Joanna, Kuszmiersz, Piotr, Mituś, Jerzy W., Püsküllüoğlu, Mirosława, Grela-Wojewoda, Aleksandra, Korkosz, Mariusz, Bazan-Socha, Stanisława
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049070/
https://www.ncbi.nlm.nih.gov/pubmed/36981837
http://dx.doi.org/10.3390/ijerph20064926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049070/
https://www.ncbi.nlm.nih.gov/pubmed/36981837
http://dx.doi.org/10.3390/ijerph20064926

Ejemplares similares